



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Telitacept

<b>Cat. No.:</b>	HY-P99568
<b>CAS No.:</b>	2136630-26-5
<b>Target:</b>	Others
<b>Pathway:</b>	Others
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Telitacept (RC18) is a fully human TACI-Fc fusion protein. Telitacept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. Telitacept can be used in research of B-cell autoimmune disease <sup>[1]</sup> .	
<b>IC<sub>50</sub> &amp; Target</b>	(BLyS)/APRIL <sup>[1]</sup>	
<b>In Vivo</b>	Telitacept (15 and 7.5mpk, i.p.) improves mouse experimental autoimmune encephalomyelitis (EAE) clinical symptoms in MOG <sub>35-55</sub> induced EAE model mice <sup>[2]</sup> .	
	MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	<b>Animal Model:</b>	MOG <sub>35-55</sub> peptide-induced EAE mice model (6- to 8-week-old, female) <sup>[2]</sup>
	<b>Dosage:</b>	15mpk and 7.5mpk
	<b>Administration:</b>	i.p.
<b>Result:</b>	Reduced the severity of tail paralyzes and limb weakness in mice, but not as high efficacy as equal dose of Secukinumab (HY-P9927). Decreased the number of infiltrating inflammatory cells around the white matter in spinal cord.	

### REFERENCES

- [1]. Yao X, et, al. Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis. *Eur J Pharm Sci.* 2021 Apr 1;159:105704.
- [2]. Yuxi Yan, et al. Experimental Autoimmune Encephalomyelitis Animal Models Induced by Different Myelin Antigens Exhibit Differential Pharmacologic Responses to Anti-Inflammatory Drugs. *Journal of Immunological Sciences.* March 31, 2022.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA